Linvoseltamab (REGN5458)

Overview

Linvoseltamab (REGN5458) is a bispecific BCMA/CD3 T cell engaging antibody.

SparkCures ID 351
Developed By Regeneron Pharmaceuticals
Generic Name Linvoseltamab (REGN5458)
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma

The following is a listing of clinical trials for patients with Smoldering Myeloma.

Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Regeneron’s linvoseltamab shows early and durable response in pre-treated MM

September 29, 2023

The objective response rate (ORR) for 200mg linvoseltamab was 71%, with 59% and 30% of patients achieving very good partial response (VGPR) and complete responses (CR), respectively.

Treatment-emergent adverse effects included cytokine release syndrome, neutropenia (low white blood cell count), cough and others. However, these were mild to moderate in severity.

Resources